Total Payments
$650,478
2024 Payments
$24,543
Companies
35
Transactions
647
Medicare Patients
5,623
Medicare Billing
$455,739
Payment Breakdown by Category
Research$630,695 (97.0%)
Food & Beverage$13,958 (2.1%)
Travel$5,686 (0.9%)
Education$139.26 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $630,695 | 42 | 97.0% |
| Food and Beverage | $13,958 | 567 | 2.1% |
| Travel and Lodging | $5,686 | 22 | 0.9% |
| Education | $139.26 | 16 | 0.0% |
Payments by Type
Research
$630,695
42 transactions
General
$19,784
605 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $569,042 | 55 | $0 (2024) |
| Eli Lilly and Company | $58,703 | 16 | $0 (2024) |
| Allergan, Inc. | $4,298 | 29 | $0 (2021) |
| Amgen Inc. | $3,949 | 127 | $0 (2024) |
| SANOFI PASTEUR INC. | $2,025 | 14 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $1,709 | 78 | $0 (2022) |
| ModernaTX, Inc. | $1,465 | 4 | $0 (2023) |
| SANOFI US SERVICES INC. | $1,094 | 3 | $0 (2018) |
| SANOFI-AVENTIS U.S. LLC | $1,043 | 50 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,003 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,543 | 30 | Eli Lilly and Company ($23,927) |
| 2023 | $576,164 | 68 | PFIZER INC. ($568,640) |
| 2022 | $1,965 | 61 | Amgen Inc. ($475.61) |
| 2021 | $32,730 | 81 | Eli Lilly and Company ($30,261) |
| 2020 | $1,227 | 59 | Amgen Inc. ($320.31) |
| 2019 | $3,126 | 85 | Eli Lilly and Company ($1,094) |
| 2018 | $5,004 | 120 | Allergan Inc. ($1,125) |
| 2017 | $5,720 | 143 | Allergan Inc. ($2,133) |
All Payment Transactions
647 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: Cardiology | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $5.43 | General |
| Category: Cardiology | ||||||
| 09/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,262.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,601.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,188.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,857.00 | Research |
| Study: A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | ||||||
| 09/16/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: Inflammation | ||||||
| 09/11/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Obesity | ||||||
| 08/28/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $121.82 | General |
| Category: Obesity | ||||||
| 08/05/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: Inflammation | ||||||
| 08/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Diabetes | ||||||
| 06/27/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Obesity | ||||||
| 06/26/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: Inflammation | ||||||
| 06/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: DIABETES | ||||||
| 06/07/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $8.16 | General |
| Category: Obesity | ||||||
| 05/23/2024 | PFIZER INC. | VYNDAMAX (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/20/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: Inflammation | ||||||
| 05/14/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $25.82 | General |
| Category: Bone Health | ||||||
| 04/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $10.91 | General |
| Category: Cardiology | ||||||
| 04/05/2024 | Eli Lilly and Company | — | — | In-kind items and services | $19.04 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 03/27/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: VACCINES | ||||||
| 03/18/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: PAIN | ||||||
| 03/14/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: INFECTIOUS DISEASES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $568,597 | 7 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $29,440 | 2 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $13,684 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | Eli Lilly and Company | $6,188 | 1 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $4,703 | 2 |
| A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent,Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 years of age) and Adolescents,(10 to 17 years of age) | SANOFI PASTEUR INC. | $2,025 | 14 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $1,425 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $1,094 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $920.00 | 3 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $920.00 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $853.65 | 1 |
| A STUDY OF RETATRUTIDE (LY3437943) ON RENAL FUNCTION IN PARTICIPANTS WITH OVERWEIGHT OR OBESITY AND CHRONIC KIDNEY DISEASE WITH OR WITHOUT TYPE 2 DIABETES | Eli Lilly and Company | $532.49 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | Eli Lilly and Company | $170.53 | 1 |
| A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 | Regeneron Pharmaceuticals, Inc. | $142.20 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,505 | 2,153 | $245,908 | $131,123 |
| 2022 | 17 | 1,529 | 2,197 | $244,508 | $129,186 |
| 2021 | 18 | 1,399 | 1,843 | $202,683 | $107,916 |
| 2020 | 18 | 1,190 | 1,593 | $182,636 | $87,513 |
Total Patients
5,623
Total Services
7,786
Medicare Billing
$455,739
Procedure Codes
68
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 478 | $111,431 | $48,247 | 43.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 180 | 180 | $44,147 | $25,265 | 57.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 209 | 378 | $21,168 | $14,905 | 70.4% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 46 | 46 | $13,800 | $12,979 | 94.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 98 | 99 | $7,225 | $7,057 | 97.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 43 | 59 | $9,257 | $4,303 | 46.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 102 | 103 | $5,220 | $3,442 | 65.9% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 43 | 106 | $9,559 | $3,378 | 35.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 127 | 127 | $5,267 | $2,624 | 49.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 173 | 283 | $5,660 | $2,377 | 42.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 31 | 36 | $2,952 | $2,186 | 74.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 50 | 50 | $2,534 | $1,671 | 65.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 66 | 73 | $2,190 | $1,552 | 70.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 74 | 92 | $4,423 | $1,089 | 24.6% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 28 | 43 | $1,075 | $48.26 | 4.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 224 | 434 | $100,853 | $45,057 | 44.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 158 | 158 | $38,751 | $22,711 | 58.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 192 | 358 | $20,048 | $14,178 | 70.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 43 | 43 | $15,796 | $7,889 | 49.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 108 | 112 | $7,280 | $7,154 | 98.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 76 | $12,034 | $5,790 | 48.1% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 22 | 22 | $4,950 | $4,871 | 98.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 112 | 116 | $5,879 | $3,849 | 65.5% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 38 | 115 | $10,371 | $3,506 | 33.8% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 25 | 25 | $3,375 | $3,295 | 97.6% |
About Dr. Hessam Aazami, M.D
Dr. Hessam Aazami, M.D is a General Practice healthcare provider based in Canoga Park, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144299173.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hessam Aazami, M.D has received a total of $650,478 in payments from pharmaceutical and medical device companies, with $24,543 received in 2024. These payments were reported across 647 transactions from 35 companies. The most common payment nature is "" ($630,695).
As a Medicare-enrolled provider, Aazami has provided services to 5,623 Medicare beneficiaries, totaling 7,786 services with total Medicare billing of $455,739. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Ad
Practice Information
- Specialty General Practice
- Location Canoga Park, CA
- Active Since 03/14/2006
- Last Updated 05/06/2010
- Taxonomy Code 208D00000X
- Entity Type Individual
- NPI Number 1144299173
Products in Payments
- ZAVZPRET (Drug) $568,597
- Repatha (Biological) $1,720
- SAR439977 (Drug) $1,094
- XARELTO (Drug) $1,084
- Aimovig (Biological) $923.05
- JARDIANCE (Drug) $870.95
- BOTOX (Biological) $852.68
- Otezla (Drug) $716.76
- INVOKANA (Drug) $569.60
- FARXIGA (Drug) $541.97
- SOLIQUA (Drug) $410.00
- UBRELVY (Drug) $405.41
- Vascepa (Drug) $388.13
- Trulance (Drug) $375.00
- NURTEC ODT (Drug) $352.28
- JANUVIA (Drug) $338.71
- XIFAXAN (Drug) $313.30
- Prolia (Biological) $238.42
- Kerendia (Drug) $225.36
- SOLIQUA 100/33 (Biological) $221.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Canoga Park
Robert Rigg, M.d, M.D
General Practice — Payments: $8,761
General Practice $8,761
Dr. Mary Ditto, D.d.s, D.D.S
General Practice — Payments: $4,146
General Practice $4,146
Roman Pidkova, Dds, Apc, DDS, APC
General Practice — Payments: $3,462
General Practice $3,462
Erwin Abad, D.d.s, D.D.S
General Practice — Payments: $940.27
General Practice $940.27
Dr. Nikolaos Theodorou, Dds, DDS
General Practice — Payments: $398.98
General Practice $398.98
Dr. Larisa Theodorou, Dds, DDS
General Practice — Payments: $398.54
General Practice $398.54